CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
UK court imposes safety rules on off-label use of Avastin in wet-AMDBayer has said a new UK court ruling could limit off-label use of Roche’s Avastin in ophthalmology by Share XUK court imposes safety rules on off-label use of Avastin in wet-AMDhttps://pharmaphorum.com/news/uk-appeal-court-upholds-use-of-avastin/
Jefferies heads $1 billion fundraiser for COVID-19 packaging driveAs research efforts to find drugs effective against COVID-19 gather pace, a public-private partnership has been set up Share XJefferies heads $1 billion fundraiser for COVID-19 packaging drivehttps://pharmaphorum.com/news/jefferies-heads-1-billion-fundraiser-for-covid-19-packaging-drive/
AbbVie won’t enforce patents for COVID-19 drug candidate KaletraAbbVie has said it won’t defend patent rights to its HIV therapy Kaletra in the hope that it Share XAbbVie won’t enforce patents for COVID-19 drug candidate Kaletrahttps://pharmaphorum.com/news/abbvie-wont-enforce-patents-for-covid-19-drug-candidate-kaletra/
FDA backs Glenmark’s rival to AZ’s blockbuster FarxigaAstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to Share XFDA backs Glenmark’s rival to AZ’s blockbuster Farxigahttps://pharmaphorum.com/news/fda-tentatively-backs-glenmarks-farxiga-generic/
Trump pledges access to malaria drug chloroquine for COVID-19President Donald Trump thrust a decades old malaria drug called chloroquine into the forefront of efforts to treat Share XTrump pledges access to malaria drug chloroquine for COVID-19https://pharmaphorum.com/news/trump-pledges-access-to-malaria-drug-chloroquine-for-covid-19/
NICE names Gillian Leng as CEO, replacing Andrew DillonNICE has appointed Prof Gillian Leng as its new chief executive, completing its top leadership search after new Share XNICE names Gillian Leng as CEO, replacing Andrew Dillonhttps://pharmaphorum.com/news/nice-names-gillian-leng-as-ceo-replacing-andrew-dillon/
FDA gives Lilly’s Olumiant breakthrough status for hair lossEli Lilly’s Olumiant is facing tough competition in its approved rheumatoid arthritis indication, but could take the lead Share XFDA gives Lilly’s Olumiant breakthrough status for hair losshttps://pharmaphorum.com/news/fda-gives-lillys-olumiant-breakthrough-status-for-hair-loss/
MPs back Nebhrajani as NICE’s new chair after vetting meetingSharmila Nebhrajani has been confirmed as the new chair of the National Institute for Health and Care Excellence Share XMPs back Nebhrajani as NICE’s new chair after vetting meetinghttps://pharmaphorum.com/news/mps-back-nebhrajani-as-nices-new-chair-after-vetting-meeting/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
After rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival AjovySeveral months after turning down NHS funding for Novartis’ CGRP inhibitor Aimovig for migraine prevention, NICE has backed Share XAfter rejecting Novartis’ Aimovig for migraine, NICE backs Teva rival Ajovyhttps://pharmaphorum.com/news/novartis-aimovig-for-migraine-nice-backs-teva-rival/
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbusterTen drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy Share XAmgen/Allergan’s rituximab biosimilar could be $4bn blockbusterhttps://pharmaphorum.com/news/amgen-allergans-rituximab-biosimilar-could-be-4bn-blockbuster/
NICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmaNICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma in Share XNICE rejects NHS funding Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/nice-rejects-nhs-funding-sanofi-regenerons-dupixent-in-asthma/
NICE chair nominee Nebhrajani to face MP scrutiny next weekThe UK government’s preferred candidate to chair NICE – Sharmila Nebhrajani OBE – is due to be quizzed Share XNICE chair nominee Nebhrajani to face MP scrutiny next weekhttps://pharmaphorum.com/news/nice-chair-nominee-nebhrajani-to-face-mp-scrutiny-next-week/
Girl loses High Court battle over NICE review of BioMarin’s PKU drugAn 11-year-old girl with the rare disease phenylketonuria (PKU) has lost a legal battle in the High Court Share XGirl loses High Court battle over NICE review of BioMarin’s PKU drughttps://pharmaphorum.com/news/girl-loses-high-court-battle-over-nice-review-of-biomarins-pku-drug/
FDA starts review of Pfizer, Lilly’s non-opioid painkillerAfter years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, Share XFDA starts review of Pfizer, Lilly’s non-opioid painkillerhttps://pharmaphorum.com/news/fda-starts-review-of-pfizer-lillys-non-opioid-painkiller/
